Genmab — Maj 2021
-
•Look similar to or be capable of being mistaken for the name of a currently marketed product (e.g., should not increase the risk of confusion or medical errors with the product and/or other products in the clinical setting)•Look similar to or otherwise connote the name of the license holder•Be too similar to any other FDA-designated nonproprietary name suffix"
-
Fra Janssens artikel: Dr. Knoblauch is hopeful that the drug will prove to be an effective treatment for other types of cancer, as well.
“There are several other types of tumors we can explore where one of the same genes that our bispecific binds to is overexpressed,” he says. “I’m looking forward to seeing if there is potential for this drug to help patients with other types of cancers, too.” https://www.jnj.com/innovation/journey-to-fda-approval-non-small-cell-lung-cancer-treatment
-
Enig Stroka. Jeg lægger artiklen op i debatten.
-
-
Bibob..Det er utrættelige E L som har lagt den ud via link til Janssens opslag på Twitter. Tak til ham.
-
Kan tanken være, at licensomkostninger (hos JNJ) på 15-17 %, måske 20 % fladt på Dara i fremtiden, belaster nøgletal - lige så vel, som Genmab på Royalty-omsætningen har et "flot" nøgletal med en overskudgrad på måske 90-95 %. Når pengemaskinen JnJ på relativ kort tid kan finansiere et Genmab køb, kan man løfte overskudsgraden med op til 20 % af hele Dara omsætningen plus alt det andet der kommer oven i hatten.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind